Novartis Forecast, price target & analysts
Novartis Target price 2025 - Analyst rating & recommendation
Novartis Classifications & Recommendation:
Novartis Price Target
| Target Price | CHF98.86 |
| Price | CHF90.63 |
| Potential | 9.09% |
| Number of Estimates | 21 |
| 21 Analysts have issued a price target Novartis 2026 . The average Novartis target price is CHF98.86. This is 9.09% higher than the current stock price. The highest price target is CHF120.82 33.31% , the lowest is CHF73.66 18.72% . | |
| A rating was issued by 28 analysts: 5 Analysts recommend Novartis to buy, 19 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2026 of 9.09% . Most analysts recommend the Novartis stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2029
20 Analysts have issued a sales forecast Novartis 2025 . The average Novartis sales estimate is CHF43.9b . This is 0.91% lower than the revenue of the last 12 months(TTM). The highest sales forecast is CHF45.8b 3.45% , the lowest is CHF41.6b 6.11% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF44.3b | 8.52% |
|---|---|---|
| 2025 | CHF43.9b | 0.91% |
| 2026 | CHF44.8b | 2.09% |
| 2027 | CHF46.0b | 2.68% |
| 2028 | CHF47.8b | 3.83% |
| 2029 | CHF49.0b | 2.62% |
16 Analysts have issued an Novartis EBITDA forecast 2025. The average Novartis EBITDA estimate is CHF17.8b . This is 5.78% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF19.0b 0.46% , the lowest is CHF14.3b 24.29% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF18.8b | 3.79% |
|---|---|---|
| 2025 | CHF17.8b | 5.23% |
| 2026 | CHF18.2b | 2.40% |
| 2027 | CHF19.0b | 4.17% |
| 2028 | CHF19.9b | 4.64% |
| 2029 | CHF22.8b | 14.71% |
EBITDA Margin
| 2024 | 42.40% | 4.36% |
|---|---|---|
| 2025 | 40.55% | 4.36% |
| 2026 | 40.68% | 0.32% |
| 2027 | 41.27% | 1.45% |
| 2028 | 41.59% | 0.78% |
| 2029 | 46.49% | 11.78% |
13 Novartis Analysts have issued a net profit forecast 2025. The average Novartis net profit estimate is CHF11.0b . This is 6.47% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF12.5b 21.12% , the lowest is CHF8.6b 16.52% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF10.3b | 18.97% |
|---|---|---|
| 2025 | CHF11.0b | 6.47% |
| 2026 | CHF11.7b | 6.92% |
| 2027 | CHF12.5b | 6.92% |
| 2028 | CHF13.9b | 10.68% |
| 2029 | CHF15.1b | 8.83% |
Net Margin
| 2024 | 23.22% | 25.33% |
|---|---|---|
| 2025 | 24.95% | 7.44% |
| 2026 | 26.13% | 4.73% |
| 2027 | 27.21% | 4.13% |
| 2028 | 29.01% | 6.62% |
| 2029 | 30.76% | 6.03% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
13 Analysts have issued a Novartis forecast for earnings per share. The average Novartis EPS is CHF5.55 . This is 6.53% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF6.31 21.11% , the lowest is CHF4.35 16.51% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF5.21 | 18.97% |
|---|---|---|
| 2025 | CHF5.55 | 6.53% |
| 2026 | CHF5.93 | 6.85% |
| 2027 | CHF6.34 | 6.91% |
| 2028 | CHF7.02 | 10.73% |
| 2029 | CHF7.64 | 8.83% |
P/E ratio
| Current | 17.39 | 29.87% |
|---|---|---|
| 2025 | 16.34 | 6.04% |
| 2026 | 15.28 | 6.49% |
| 2027 | 14.29 | 6.48% |
| 2028 | 12.91 | 9.66% |
| 2029 | 11.87 | 8.06% |
Based on analysts' sales estimates for 2025, the Novartis stock is valued at an EV/Sales of 4.29 and an P/S ratio of 3.92 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.25 | 6.52% |
|---|---|---|
| 2025 | 4.29 | 0.84% |
| 2026 | 4.20 | 2.05% |
| 2027 | 4.09 | 2.61% |
| 2028 | 3.94 | 3.69% |
| 2029 | 3.84 | 2.55% |
P/S ratio
| Current | 3.88 | 3.16% |
|---|---|---|
| 2025 | 3.92 | 0.92% |
| 2026 | 3.84 | 2.05% |
| 2027 | 3.74 | 2.61% |
| 2028 | 3.60 | 3.69% |
| 2029 | 3.51 | 2.55% |
Current Novartis Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Apr 07 2025 |
| ARGUS RESEARCH CORPORATION |
Hold
➜
Hold
|
Unchanged | Apr 06 2025 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Apr 06 2025 |
| DAY BY DAY |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
| REDBURN ATLANTIC |
Sell
➜
Sell
|
Unchanged | Mar 21 2025 |
| GUGGENHEIM SECURITIES LLC |
Neutral
➜
Neutral
|
Unchanged | Mar 17 2025 |
| CHINA MERCHANTS SECURITIES CO., LTD |
Buy
➜
Buy
|
Unchanged | Mar 04 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Apr 07 2025 |
|
Unchanged
ARGUS RESEARCH CORPORATION:
Hold
➜
Hold
|
Apr 06 2025 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Apr 06 2025 |
|
Unchanged
DAY BY DAY:
Buy
➜
Buy
|
Mar 23 2025 |
|
Unchanged
REDBURN ATLANTIC:
Sell
➜
Sell
|
Mar 21 2025 |
|
Unchanged
GUGGENHEIM SECURITIES LLC:
Neutral
➜
Neutral
|
Mar 17 2025 |
|
Unchanged
CHINA MERCHANTS SECURITIES CO., LTD:
Buy
➜
Buy
|
Mar 04 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
